

Abstract


The present comprehensive study was designed to investigate the changes in some biochemical parameters and determine the risk factors in sera samples of patient with myocardial infarction (MI) [history of diabetes mellitus (DM) type 1, hypertension (blood pressure BP), and DM+ BP+smoking]. Sixty four patients with MI attending to Merjan Teaching Hospital in Hilla City, were included in the present study. Also thirty two healthy individuals of matched age and gender were utilized as control. The main measurements included the following biochemical measurements: -Ceruloplasmin (CP), copper (Cu), total protein (TP), albumin (Alb.), globulin (Glo), total cholesterol (TC), triglyceride (TG), and total bilirubin (TB) concentrations, also Alb./Glo. ratio, TC/Alb ratio, CP oxidase activity, CP oxidase specific activity and Cu conc. / CP oxidase activity ratio in sera of healthy (control) and patients with MI (history of DM, BP and DM+BP+smoking). The results revealed a highly significant increase ($p < 0.001$) in the CP, TP, Glo, TG, TB concentrations, Alb./Glo. ratio, CP oxidase activity, specific activity and Cu conc./CP oxidase activity ratio in sera of patients with MI (DM+BP+smoking), while the same parameter referred significant increase ($p < 0.01$) in patients with MI (DM or BP) in comparison with control group. But Alb. concentration show significant decrease in the all groups ($p < 0.001$), ($p < 0.01$) respectively. An important finding in this study is that biochemical risk factors appeared to occur in patients with DM+BP+smoking more the patients with DM or BP. This observation suggests that DM+BP+smoking may be more prominent risk factor for MI. Hypertriglyceridemia, but not hypercholesterolemia, is associated with MI. TC/Alb ratio is considered a better index of cardiovascular risk than serum cholesterol. CP conc., CP activity and specific activity and Cu Conc. / CP oxidase activity anew biochemical parameters and risk factors, therefore this results it is regarded us a primary indicator to MI.

Introduction

Myocardial infarction (MI), also known as coronary thrombosis, is one of the commonest causes of mortality and morbidity in adults^(1,2). MI is usually diagnosed by a history of crushing chest pain, characteristic ECG changes and cardiac muscle enzyme release. MI occurs when the supply of blood to the coronary muscle is reduced below a critical value, usually as result of atheromatous plaque rupture and overlying thrombosis.

This may be presaged by less catastrophic episodes of chest pain (angina pectoris) due to reduction of coronary perfusion caused by the narrowing of the arteries by atheromatous plaque. Biochemical tests are used as a complementary diagnostic procedures to ECG findings. Three enzymes are commonly used in the diagnosis and follow-up of the MI. These are: creatine kinase (CK), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH). Those enzymes lost their utility due to lack of specificity and limited sensitivities⁽³⁾. Among the currently available markers cardiac troponins are the most widely used due to their improved sensitivity, specificity, efficiency and low turn around time^(3,4). The combination of myoglobin with cardiac troponins I and T has further improved the accuracy in the diagnosis of acute coronary syndromes⁽³⁾. Among the other new markers of early detection of myocardial damage, heart fatty acid binding protein, ischemic modified-albumin, lipoprotein(a), remnant lipoprotein-cholesterol, glycogen phosphorylase BB and myoglobin /carbonic anhydrase III ratio seem to be the most promising^(3,5,6). Many risk factors, such as diabetes mellitus (DM), hypertension (HP), and hyperlipidemia contribute to the developing of coronary artery disease (CAD) and MI⁽⁷⁾. Lipid profile help to determine risk of (CDA)⁽⁸⁾.

Ceruloplasmin is a copper-containing, which has enzymatic activities. It is also called Ferroxidase 90% or more of total serum copper is associated with ceruloplasmin⁽⁹⁾ and the remaining 5-10% of copper is believed to be fairly loosely attached to albumin and histidine and only a trace of copper is present as free Cu^{++} ^(10, 11). CP, synthesized in the liver is multifunctional protein it can help transferrin to bind iron^(12,13).



The antioxidant protection of ceruloplasmin is derived mainly from its ability to oxidize highly toxic ferrous iron to the relatively non toxic ferric form⁽¹⁴⁾, and that helps in preventing oxidative damage of proteins, lipids, and DNA⁽¹⁵⁾.

The aim of our study is to evaluate the risk factors to the new parameters such as ceruloplasmin oxidase activity, ceruloplasmin (CP) concentration, copper(Cu) concentration, mean value of Cu concentration / CP oxidase activity, total protein, albumin, globulin concentrations, albumin/ globulin ratio in sera of healthy (control) and patients with MI (history of (DM), (BP) and DM+BP +smoking).

Patients and Methods

Chemicals: All laboratory chemical and reagent in this work were of analar grade and imported from BDH Co. and SIGMA Co

Samples:(64) patients with MI were included in this study, (divided three groups; **1**-History of DM, type 1, no=21), **2**-History of BP, systolic blood pressure(BP) more than 160 mm Hg and diastolic less than 70 mm Hg, no=19. **3**-DM + BP + smoking, no=24). Admitted to Merjan Teaching Hospital in Hilla City, over period of about eight months from March 2007 to September 2007. The diagnosis of MI was established on clinical ground. All the subjects were examined clinically and informations pertaining to age, habits and health status were recorded in special case proforma. Other group included (no=32) apparently healthy (control) with no history of MI and other disease. Venous blood samples were collected from both controls and patients(in the first day, after MI) for the estimation of serum parameters.

Total Protein Estimation: The protein content of all samples was determined by Lowery method⁽¹⁶⁾ using bovine serum albumin as standard protein for all samples.

Albumin Concentration Estimation : Serum albumin was determined by dye-binding method⁽¹⁷⁾ using kit manufactured by bioMerieux.

Globulin Concentration Estimation: The concentration of globulin in serum samples of control and patients groups was calculated, using the following equation:

$C_{glob.} = C_{Tp} - C_{alb}$, $C_{glob.}$ = concentration of globulin , C_{Tp} = concentration of total protein and C_{alb} = concentration of albumin

Ceruloplasmin Oxidase Activity Assay: The activity of ceruloplasmin oxidase was determined in serum using, the modified Rice method⁽¹⁸⁾ where as ceruloplasmin catalyzed the oxidation of p-phenylenediamine (substrate) to give blue-violet color that measured at $\lambda = 525$ nm

Copper Concentration Estimation: The copper concentration determined in serum by the atomic absorption spectrophotometry⁽¹⁹⁾.

Total cholesterol, triglyceride and total bilirubin were determined by using commercially available kits (Biomergerb kit, iMorocco kit).

Statistical Analysis: The data of the study was subjected to statistical analysis is expressed as mean \pm SD ⁽²⁰⁾. Statistical analyses were done on a computer by using the Student 't' test.

Results

Table 1 shows a significant increase in serum concentration of total protein (TP), and globulin (Glo.) Concentration between healthy and MI (DM, $P < 0.01$), MI (BP, ($P < 0.01$) and MI (DM+ BP + smoking, $P < 0.001$) patients. In contrast, the results revealed a highly significant decrease ($P < 0.001$) and ($P < 0.01$) of albumin (Alb.) concentration in the case of MI (history of DM+ BP + smoking) and MI (history of DM+ BP) respectively in comparison to that of the control group. Also Alb./ Glo. ratio show a highly significant increase ($P < 0.001$) in all patient groups.

Table 1: Total Protein (TP), Albumin (Alb.), Globulin (Glo.) Concentrations and Alb. / Glo. ratio in Sera of Control and MI Patients (Mean Value ± SD).

Groups	Sex	No.	Age(Y)	Variations			
				TP(g/dl)	Alb.(g/dl)	Glo.(g/dl)	Alb./Glo.
Control	M	18	38.6±19.2	7.74±1.24	4.43±0.61	3.21±0.61	1.12±0.31
	F	14	37.4±18.2	7.56±0.94	4.33±0.53	3.33±0.53	1.10±0.51
MI(DM)	M	11	41.3±15.2	8.99±1.2*	3.53±0.4*	5.36±0.4*	0.64±0.4**
	F	10	40.5±13.2	8.94±1.4*	3.53±0.3*	5.44±0.3*	0.65±0.4**
MI (BP)	M	10	37.3±12.2	8.67±0.9*	3.63±0.5*	5.14±0.5*	0.72±0.3**
	F	9	38.2±91.2	8.77±1.2*	3.53±0.2*	5.14±0.2*	0.67±0.2**
MI(DM+BP+smoking)	M	16	39.9±12.2	10.31±1.2* *	2.23±0.4**	8.18±0.4* *	0.27±0.4**
	F	8	41.3±10.2	10.22±1.3* *	2.31±0.3**	7.81±0.3* *	0.29±0.3**

*** (P<0.01), ** (P<0.001)**

Table 2 shows that the serum triglyceride concentration and total bilirubin significantly increased in patients with MI [DM, BP (p<0.01) and DM+ BP +smoking (p<0.001)] in comparison with healthy. On the other hand there was no significant difference in serum total cholesterol (TC) concentration between patients with MI and controls. The ratio (TC/Alb) found that patients with MI (DM and DM+ BP +smoking) should a highly significantly increase (p<0.01, p<0.001 respectively) in comparison with control, while a highly significant decrease (p<0.001) in patients with MI (BP).

Table(2):Total cholesterol(TC), Triglyceride(TG) ,Total bilirubin (TB)and Cholesterol to albumin ratio(TC/Alb) in Sera of Control and MI Patients(Mean Value ± SD).

Groups	Sex	No .	Age(Y)	Variations			
				TC mmol/L	TG mmol/L	TB μmol/L	TC/Alb.
Control	M	18	38.6± 19.2	5. 42±1.41	1.58±0.81	15.61±3.1	1.22±0.5
	F	14	37.4± 18.2	5. 32±1.21	1.56±0.77	15.56±2.7	1.22±0.4
MI(DM)	M	11	41.3± 15.2	5. 33±1.21	2.87±0.57 *	28.3±2.5*	1.50±0.4 *
	F	10	40.5± 13.2	5. 40±1.31	2.98±0.46 *	29.1±1.2*	1.52±0.5 *
MI(BP)	M	10	37.3± 12.2	5. 41±1.41	2.82±0.45 *	26.1±1.4*	0.67±0.4 **
	F	9	38.2± 91.2	5. 33±1.11	2.13±0.22 *	26.3±1.2*	0.66±0.5 **
MI(DM+ BP +smoki ng)	M	16	39.9± 12.2	5. 41±1.21	3.97±0.2* *	32.9±2.2* *	2.42±0.7 **
	F	8	41.3± 10.2	5. 39±1.22	3.88±0.4* *	32.8±2.4* *	2.33±0.6 **

***(P<0.01), ** (P<0.001)**

Table 3 shows a highly significant increase (P<0.001) in ceruloplasmin(CP) concentration and serum copper for MI (history of DM, BP and DM+ BP +smoking) patients in comparison to that of control.

Table (3): Ceruloplasmin (CP) Concentration and Copper (Cu) Concentration in Sera of Control and MI Patients (Mean Value ± SD).

Groups	Sex	No.	Age(Y)	Variations	
				CP(mg/dl)	Cu (μmol/l)
Control	M	18	38.6±19.2	48.31±2.34	5.73±0.81
	F	14	37.4±18.2	48.34±3,42	5.68±0.81
MI(DM)	M	11	41.3±15.2	72.64±4,42**	32.85±0.92**
	F	10	40.5±13.2	72.45±3,42**	31.84±0.22**
MI(BP)	M	10	37.3±12.2	65.44±3,32**	25.86±0.34**
	F	9	38.2±91.2	65.32±3,23**	26.75±0.41**
MI (DM+ BP +smoking)	M	16	39.9±12.2	76.64±3,13**	35.99±0.64**
	F	8	41.3±10.2	76.54±3,13**	37.97±0.46**

**** (P<0.001)**

The results in fig.(1) presented the mean value of ceruloplasmin oxidase activity and the specific activity fig.(2) in sera samples. The results reflect the presence of a significant increase (P<0.001) in CP oxidase activity of MI(history of DM+ BP +smoking), and significant increase (P<0.01) in MI (history of DM and BP), in comparison to that of the control group(fig.1).




Fig. (1): Ceruloplasmin Oxidase Activity(U/L) in Sera of Control and MI Patients (Mean Value \pm SD, *(P<0.01), ** (P<0.001).

Regarding the specific activity, significant increase (P<0.01) was found in both MI(history of BP and DM+ BP +smoking) in comparison to that of the control (fig.2)




Fig. (2): Specific Activity (U/mg $\times 10^{-3}$) of Ceruloplasmin Oxidase in Sera of Control and MI Patients (Mean Value \pm SD, *(P<0.01).

Table 4 shows the mean value of copper concentration / CP oxidase activity in sera samples, and reflect a significant increase (P<0.001), in MI(history of DM + BP + smoking), in comparison to that of the control. Also(P<0.01) in MI(history DM).

Table (4): Copper Concentration / CP Oxidase Activity in Sera of Control and MI Patients (Mean Value ± SD, *(P<0.01), (P<0.001).**

Groups	Sex	No.	Age(Y)	Cu / CP activity
<i>Control</i>	M	18	38.6±19.2	0.236±0.021
	F	14	37.4±18.2	0.239±0.022
<i>MI(DM)</i>	M	11	41.3±15.2	0.414±0.13**
	F	10	40.5±13.2	0.405±0.22**
<i>MI(BP)</i>	M	10	37.3±12.2	0.313±0.12*
	F	9	38.2±91.2	0.320±0.21*
<i>MI (DM+ BP +smoking)</i>	M	16	39.9±12.2	0.364±0.13**
	F	8	41.3±10.2	0.402±0.21**

Discussion

The results of this study showed a significant increase in serum total protein , total bilirubin and globulin concentrations between MI patients and control group. Therefore, it would appear that the increased susceptibility of these biochemical components may be a more prominent for MI patients (DM+BP+smoking) than for patients with MI(DM+BP)risk factors. However, a controlled prospective study is needed to investigate this further.

The reduction in sera albumin concentration(Table 1) observed in the current study may be explained as follows:-The observed reduced albumin level in sera of patient group, may be due to the role of albumin as one of the extracellular antioxidants^(21,22) where albumin constitute up to 49% of total plasma antioxidant status⁽²³⁾. Meanwhile albumin acts as sacrificial antioxidant by inhibiting the generation of free radicals through an immediate attacks of albumin molecule itself, so the radical reaction continue on albumin surface and cause damage to albumin molecule^(24,25), such damage is probably biologically insignificant, due to fact that the albumin is present in plasma in high concentration⁽²⁶⁾.

The other cause of the observed reduced albumin level in sera of patient group, may be due to liver is the site for the synthesis of most proteins including both negative acute phase reactant proteins (APR) (pre albumin and albumin) and positive APR⁽²⁷⁾. It is well known that the concentration of positive APR in serum increased in different disease, which mean that liver will be busy with synthesis of this type of APR leaving behind the synthesis of other proteins like albumin⁽²⁸⁾, also the synthesis of inflammatory cytokines, such as tumor necrosis factor- α (TNF- α) and interleukines and C-reactive protein seems to cause a reduction in albumin concentration⁽²⁹⁾.

In the current study, globulin concentration showed a significant increase in patient groups and this may attribute to that most of the positive (APR) are globulins (i.e. glycoprotein), so the increased level of globulins is due to the increased synthesis of positive APR in different disease⁽³⁰⁾.

Table 2 shows that the serum triglyceride concentration in patients with MI(DM,BP and DM+BP+smoking) were significantly higher than that in healthy controls. On the other hand, there was no significant difference in serum total cholesterol concentration between patients with MI(DM,BP and DM+BP+smoking) and controls, suggesting that hypertriglyceridemia, but not hypercholesterolemia, is associated with MI. For a long time, the association between serum triglyceride and CHD remained unclear. In a large number of both case control and cross-sectional studies, an association between hypertriglyceridemia and myocardial infarction was reported, but only in three of them⁽³¹⁻³³⁾ did the dissociation remain significant after controlling for other confounding factors. Recently, Bainton *et al.*⁽³⁴⁾ reported that serum triglyceride was an independent risk factor for CHD.

The serum total bilirubin in patients with MI(DM,BP and DM+BP+smoking) were significantly higher than that in healthy controls. Since serum total cholesterol concentration to albumin ratio (TC/Alb.) has been reported to be a better index of cardiovascular risk than serum cholesterol⁽³⁵⁾.

Ceruloplasmin is considered as one of the positive acute-phase reactants (APR). The measured increase in ceruloplasmin concentration in the present study, in sera samples of patient groups. The increased CP concentration in sera samples result from its increased synthesis by liver, as one of the acute phase proteins which their concentration increases upon different diseases including tumors⁽³⁶⁾. Ceruloplasmin is an enzyme which has a role as an antioxidant⁽³⁷⁾. The unbalanced production of reactive oxygen intermediates have been postulated to play a role in the pathogenesis of cancer⁽³⁶⁾.

In this study, CP oxidase activity and specific activity were increased, The increase of ceruloplasmin activity may be associated with enhanced synthesis of ceruloplasmin in the liver as one of the positive acute phase reactant protein⁽³⁸⁾ which their levels increased upon malignancies.

It was reported that ceruloplasmin plays an important role in protecting a variety of tissues from free radical injury⁽³⁹⁾, the antioxidant protection of CP drives mainly from its ability to oxidize polyamines⁽⁴⁰⁾, also it can play an important role in preventing the formation of free radicals by controlling the levels of highly toxic iron. Most evidence points to CP ferroxidase activity as an antioxidant activity; conversion of Fe^{+2} to Fe^{+3} may reduce the oxidation by inhibition of the Fenton reaction (which requires reduced metal), by decreasing the amount of the pro-oxidant Fe^{+2} or an $\text{Fe}^{+2} / \text{Fe}^{+3}$ complex or by causing iron sequestration by apo-transferrin^(41,42).

Copper and ceruloplasmin are usually closely correlated with each other, since ceruloplasmin is the major copper-binding protein (over 95% of plasma copper is bound to CP). Copper helps to protect the heart by increasing HDL⁽⁴³⁾.

The [Cu]/CP activity ratio reflect the concentration of Cu that is either bound to albumin or free copper. This form of Cu is consider to be one of the pro-oxidants in the body, where transition metals such as Fe^{+2} or Cu^{+} , catalyze formation of the hydroxyl radical (OH) from hydrogen peroxide in the nonenzymatic Fenton reaction.


Conclusions

The overall results of the present study that is summarized in the following table:

Parameters	Myocardial Infraction(MI)Patients		
	MI(DM)	MI(BP)	MI(DM+BP+smoking)
Total Protein(TP) Conc.	↑	↑*	↑**
Albumin(Alb.) Conc.	↓	↓*	↓**
Globulin (Glo.) Conc.	↑	↑*	↑**
Alb./ Glo. Ratio	↓**	↓**	↓**
Total cholesterol(TC) Conc.	↔	↔	↔
Triglyceride(TG) Conc.	↑	↑*	↑**
Total bilirubin (TB) Conc.	↑	↑*	↑**
Cholesterol / albumin ratio(TC/Alb)	↑	↓*	↑*
Ceruloplasmin(CP) Conc.	↑*	↑**	↑**
Copper (Cu)Conc.	↑**	↑**	↑**
Ceruloplasmin Activity.	↑**	↑**	↑**
Ceruloplasmin Specific Activity	↔	↑*	↑*
Cu Conc. / CP Oxidase Activity	↑*	↑*	↑**

MI(DM):Myocardial Infarction(diabetes mellitus),
MI(BP):Myocardial Infarction(blood pressure),
MI(DM+BP+smoking):Myocardial Infarction(diabetes mellitus+ blood pressure+ smoking). no change(as in control), Increase , Decrease and (*=p<0.05, ** = p < 0.001)

The overall conclusions of the present study can be summarized in the following diagram :



Acknowledgements

Thanks and praise be to God, and prayer and peace upon his messenger Mohammed, and his own pure relatives and best colleagues. I would like to express my sincere gratitude to Dr. Amjad and Khowla A. AL-Shemran for providing all samples (MI) from Merjan Teaching Hospital, Hilla City .

Reference

- Richared N., Fogoros MDS. (2007). Heart disease blog. About Corn health's disease and condition content medical review board.
- Allan G.,Robert A.Cowan,Denis St.J.O`Reilly,Michael J.Stewart and James Shepherd (1999):Clinical biochemistry.2^{ed} edition,Churchill livingstone Company Philadelphia pp48-49.
- Nigam P. (2007):Biochemical markers of myocardial injury.Indian J.oh Clinical Biochemestery/22(1)10-17.
- Bodor GS. Cardiac troponins(2004): A decade of change in cardiac marker testing. Lab Medica.- International. 21 No. 2 3-4, 13-14.
- Olusi S.,Prabha.K.,Sugathan T.(1999):Biochemical risk factors for myocardial infarction among south asian immigrants arabs. Annals of Saudi Mdicine, 19,No. 2.
- Kwon H.J., Eun J. Seo and Ki.O.Min.(2003) :The influence of haemolysis, turbidity and icterus on the measurements of CK-MB, troponin 1 and myoglobin. Clinical Chemistry and Laboratory Medicine .41, 3, 360-364.
- Cotran RS., Kumar V., Robbins SL.(1994). Robbins pathologic basis of disease. 5th ed. Philadelphia, PA:WB Saunders Co.
- Ryan TJ., Antman EM, Brooks NH., et al. (1999) update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. J AM Coll Cardiol. 1999-34:890-911 and circulation.
- Bishop M., Fody E., Schoeff L., (2005): Clinical chemistry principles procedures correlations. 5thed Lipicott Williums and Wilkins PP 196 philadlphia
- Lau S.J., AND Sakar B., (1981): The interaction of copper (II) and glycyL-histtidyl L-Lysine a growth-modulating-tripeptide from plasma. Biochem J. 199:646-656
- Burtis C.A., & Ashwood E.R., (1996):"Tetiz Fundamentals of Clinical Chemistry" 4th ed. Eds. W.B. Saunders Company Philadelphia Pp 272-275.

- Musci G., Bonacconsi D., Patti M.C., Petruzzeli R., (1996): Divalent cation binding to ceruloplasmin. *Biometal* 9:66-72
- Young S.N., and Curzon G., (1972): A method of obtaining linear reciprocal plots with ceruloplasmin and application in a study of the kinetic parameters of ceruloplasmin substrates. *Biochem J* 129:273-283
- Ivanova E., and Ivanova B., (2000): Mechanism of extracellular antioxidant defense. *Experimental pathology and parasitology* 4:49-58
- Kang J.H., (2006): Oxidative modification of human ceruloplasmin by methylglyoxal: An in vitro study. *J. Biochem. Mol. Biol.* 39(3):335-338
- Stoscheck C.M. In "Methods in Enzymology", Ed. Deutscher M.P., Academic Press. Inc., U.S.A., 1990, Vol. 182, pp. 57-60.
- Doumas B.T., Watson W.A., and Biggs H.G., (1971): Albumin standard and the measurement of albumin with bromocresol green. *Clin Chim Acta* 31: 87-96
- Rice E.W., (1962): Ceruloplasmin assay in serum: standardization of ceruloplasmin activity in terms of international enzyme unit "standard"
- Robinson J.W., (1973): "Atomic absorption spectroscopy" 2nd ed. Marcel Dekker New York
- Paul Y. (2005) "Chemical Calculations at a glance" , 2nd ed., Blackwell publishing
- Kouoh F., Gressier B., & Luyckx M., (1999): Antioxidant properties of albumin: effect on oxidative metabolism of human neutrophil granulocytes. *FEBS Lett* 54:197-200
- Gopinathan V., Miller N.J., Milner D., & Rice-Evans C.A., (1994): Bilirubin and ascorbate. Antioxidant activity in neonatal plasma. *FEBS Lett* 349:197-200
- Gutteridge J.M.C., & Wikins S., (1983): Copper salt dependent hydroxyl radicals formation damage to proteins acting as antioxidants. *Biochem. Acta* 759:38
- Marx G., & Chevion M., (1985): Site-specific modification of albumin by free radicals. *Biochem J* 236:397-400

- Halliwell B., &Gutteridge J.M.C., (1986): Oxygen free radicals and iron in relation to biology and medicine : some problems and concepts. Arch. Biochem. Biophys. 246: 501-514
- Ovesen L., Hannibal J., &Mortensen E.L., (1993): "The relationship of weight loss, dietary intake and quality of life in ambulatory patients with ca*ncer of the lung, breast and ovary" Nutr. Cancer 19(2): 159-167
- Ryffel B., Car b.d., &Woerly G., (1994): Long term interleukin-6 administration stimulates in a small primate the marmoset. Blood 83:2093-2102
- AI-Rawi N.H., (2001): Measurment of trace elements, enzymes, proteins in saliva, serum and tissue extracts in patients with oral cancer. Ph.D Thesis college of Dentistry Baghdad university.
- Emerson T.E.,(1989):Unique features of albumin:A review.Mod. 17:690-694.
- Kaplan L.A., Pesce A.J., and Kazmierczak S.C., (2003): Clinical Chemistry "Theory, Analysis, Correlation" 4th ed. Eds Mosby.
- Fager G. Wiklund O, Olofsson. SO, Silhemsén I., I.ktn dijmers G.(1981) Multivariate analyses of serum apolipoproteins and risk factors in relation to acute myocardial infarction Arteriosclerosis:1 ;273-9.
- Hamsi AM. Walldius G. Dahlen G. Johansson B. De Faise U.(1989): Serum LP and apoLP in voing male survivors inyocardial infarction Atherosclerosis:77:131-8.
- AI-Mutaseb N. Ilayal N. AI-Khafaji M.(1989) :lipoproteins and apolipoproteins in young male survivors of myocardial inflection Atherosclerosis:77:131-8.
- Bainion D. Millei NF. *et al* (1992)Plasma triglyceride and high-density lipoprotein cholesterol as predictors ischaemic heart disease in British men. Br Heart.1:68:60-6
- Nanji AA, Reddy S.(1983) Use of total cholesterol/albumin ratio as an alternative to high-density lipoprotein cholesterol measurement .J.Clinical Pathol:36:716-8.

- Gutteridge J.M.C., (1983):Antioxidant properties of ceruloplasmin towards iron and copper dependent oxygen radical formation. FEBS Lett, 157:37-40.
- Fridovich I., (1979): The biology of oxygen radicals. Science 201:875-880
- Fleming R.E., and Gittin J.D., (1991): Induction of ceruloplasmin gene expression in rat lung during inflammation and hypoxia. Am. J. Physiol 266:L68-L74.
- Louro M.O., Paseiro M.J., Gelabert M., & Tufor J.C., (1994):Serum immunoreactive ceruloplasmin and its oxidative activity in patients with brain tumors. Clin Chem Enzyme Comms 6: 263-267
- Guttridge J.M.C., (1978): Ceruloplasmin a plasma protein enzyme. antioxidant. Am Clin. Biochem 15: 293-296
- Gutteridge J.M.C.&Wilkins S., (1986):Antioxidant properties of the proteins ceruloplasmin, albumin and transferrin. A study of their activity in serum and synovial fluid from patients with rheumatoid Biochem. Biophys.Acta869:119.
- Fridovich L, (1978): The biology of oxygen radicals. Science 201:875-880
- Dmvasudean M. (2001): Textbook of biochemistry for medical students .Jaypeebrothers medical publishers (p)LTD, New Delhi.